Justin Stebbing, Anne Phelan, Ivan Griffin, Catherine Tucker, Olly Oechsle, Dan Smith, Peter Richardson

“Whilst we wait for a cure, could Baricitinib act as a potential treatment for 2019-nCoV acute respiratory disease?” TMLEP Member, Justin Stebbing explores.

TMLEP Member, Justin Stebbing and his team research Baricitinib as potential treatment for 2019-nCoV.

2019-nCoV is rapidly spreading across all continents and it is clear there is an increasing need for medicines that can aid patients whilst we await a vaccine. Research has shown there are few compounds which are likely to have an effective impact. TMLEP Member, Justin Stebbing explores the effectiveness of Baricitinib, which is predicted to reduce the ability of the virus to infect lung cells.

To read the full papers click below.

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

COVID-19 combining antiviral and anti-inflammatory treatments

THEMIS at the RCOG World Congress 2025

We’ve partnered with the RCOG on a number of occasions, and this event gave us another brilliant opportunity to reaffirm our long-term commitment to supporting those working in this discipline.

THEMIS and QBE Forge Strategic Partnership to Shape the Future of Medical Malpractice Indemnity

THEMIS is pleased to announce a five-year capacity agreement with QBE, one of the world’s leading insurers. This partnership reflects a shared commitment to providing the healthcare sector with a stable, robust, and future-focused indemnity solution.

Is Your Private Practice Really Safe?

If your provider is discretionary, they are not legally bound to support you. While they may offer help in some cases, they aren’t obligated to do so and each case is evaluated on its own merits, meaning they can choose whether to provide support or not.